Telix Pharmaceuticals (NASDAQ:TLX) Hits New 52-Week Low - What's Next?

Key Points

• Telix Pharmaceuticals hit a new 52-week low trading at $12.90 before closing at $13.59 with a trading volume of 55,378 shares.
• Analysts from HC Wainwright, Wedbush, and William Blair have provided positive ratings, setting price targets of $23.00 and $22.00 respectively, suggesting potential for growth.
• Recent institutional investments included new stakes worth between $170,000 and $451,000 by several firms, indicating interest in TLX despite its current price drop.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $12.90 and last traded at $13.59, with a volume of 55378 shares. The stock had previously closed at $13.59.

Analyst Upgrades and Downgrades

TLX has been the subject of several research analyst reports. William Blair reaffirmed an "outperform" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. Wedbush reaffirmed an "outperform" rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Thursday, June 12th. Finally, HC Wainwright initiated coverage on Telix Pharmaceuticals in a report on Thursday, July 3rd. They set a "buy" rating and a $23.00 price target for the company.

Telix Pharmaceuticals Price Performance

The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 0.99. The firm's 50 day simple moving average is $15.80 and its 200-day simple moving average is $16.82.

Institutional Investors Weigh In On Telix Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Private Advisor Group LLC purchased a new stake in Telix Pharmaceuticals during the first quarter worth about $170,000. Blair William & Co. IL acquired a new position in Telix Pharmaceuticals during the second quarter worth about $217,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $297,000. ABC Arbitrage SA acquired a new stake in Telix Pharmaceuticals during the 1st quarter valued at $451,000. Finally, Pier Capital LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter valued at $3,037,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.